Provided by Tiger Trade Technology Pte. Ltd.

Global X Genomics & Biotechnology ETF

68.75
+2.924.44%
Post-market: 68.810.0611+0.09%19:30 EDT
Volume:24.34K
Turnover:1.66M
Market Cap:102.06M
PE:- -
High:68.87
Open:66.43
Low:66.35
Close:65.83
52wk High:74.19
52wk Low:40.17
Shares:1.48M
Float Shares:1.48M
Volume Ratio:0.38
T/O Rate:1.64%
Dividend:0.65
Dividend Rate:0.95%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Moderna Has Surged 660% Year-To-Date, Joining The Nasdaq 100 As BofA Raises Its Price Target

Reuters
·
8 hours ago

Moderna Inc. Stock Advances 14.2%, Outperforms Peers

Dow Jones
·
14 hours ago

S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT

Reuters
·
15 hours ago

Moderna Stock (MRNA) Climbs 13% to Top Its 52-Week High — Here’s Why

TIPRANKS
·
16 hours ago

Moderna up over 11%, on Track for Highest Close Since January 2022

Dow Jones
·
17 hours ago

Sector Update: Healthcare

MT Newswires Live
·
17 hours ago

Flu Season is Already Here. Here's What to Know About This Year's Flu Shots.

Dow Jones
·
18 hours ago

Vertex and Moderna Advance CF mRNA Therapy: What VX-522 Trial Completion Means for Investors

TIPRANKS
·
18 hours ago

Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand

MT Newswires Live
·
18 hours ago

Top Midday Gainers

MT Newswires Live
·
19 hours ago

Moderna Stock Surges Over 10% to Hit New Recent High: Melanoma Vaccine Data Set for ESMO, BofA Raises Price Target to $200

TradingKey
·
Yesterday

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-10-09

Reuters
·
Yesterday

Market Chatter: Moderna, Other Vaccine Developer Stocks Rise as NIH Plans to Expedite Cancer Vaccines

MT Newswires Live
·
Yesterday

NIH Plans to Expedite Cancer Vaccines, NYT Reports; Vaccine Developer Shares Jump

MT Newswires Live
·
Yesterday

BofA Securities Adjusts Price Target on Moderna to $200 From $170, Maintains Neutral Rating

MT Newswires Live
·
Yesterday

Moderna Inc Stock (MRNA) Moved Up by 7.63% on Oct 9: A Full Analysis

TradingKey
·
Yesterday

FDA Grants Breakthrough Device Designation to Natera Multi-Cancer Blood Test

Reuters
·
Yesterday

FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

THOMSON REUTERS
·
Yesterday

Learn Why The Bull Case For Moderna Stock Could Change Following COO Appointment

Simply Wall St.
·
Yesterday

Everest Medicines Appoints Ex-Moderna Executive Lakshmi Srinivasan as Head of Translational Medicine

Reuters
·
Yesterday